Vogenx Inc.

VOGX

NASDAQHealthcareBiotechnology

在 GoAI 中打開

前收盤價

US$32.50

−US$1.63 · -4.78%

9月18日下午4:00 ET

公司概況

公司網站

Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: James Green
上市以來: 2026年8月12日
僱員: 4

市場位置

日內區間

目前US$32.50

US$31.495US$38.41

52週區間

目前US$32.50

US$12.95US$38.41

開盤價: US$34.47
前收盤價: US$34.13
成交量: 50.75萬; 2.32× 平均值
平均成交量: 21.85萬; 日均成交量
市值: 4.52億 USD
貝塔: 0; 市場參考 1
50天平均值: US$28.4652; 高於平均水平+14.17%
200天平均值: US$28.4652; 高於平均水平+14.17%

VOGX 訊息

prnewswire.com2026年8月17日

Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering

LOS ANGELES and NEW YORK, Aug. 17, 2026 /PRNewswire/ -- JonesTrading Institutional Services LLC ("Jones") today announced that it served as sole book-running manager for the $81.3 million initial public offering of…

閱讀原始碼

accessnewswire.com2026年8月13日

Vogenx Announces Closing of Initial Public Offering

RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of…

閱讀原始碼

accessnewswire.com2026年8月11日

Vogenx Announces Pricing of Initial Public Offering

RALEIGH, NC / ACCESS Newswire / August 11, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of…

閱讀原始碼